False
September 25, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the regulatory, manufacturing, investment, and commercialization trends signaling a new phase for advanced therapies
1 min read
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
View Profile
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
All the latest Medicine Maker articles.
September 21, 2026
From isotope supply to reimbursement, the practical challenges shaping real-world delivery in oncology
5 min read
September 21, 2026
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
2 min read
September 18, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale
1 min read
September 17, 2026
What one policy change would accelerate progress in drug development and manufacturing? We asked the 2026 Power List.
8 min read
September 16, 2026
Three deaths linked to immune effector cell-associated hemophagocytic syndrome prompt Novartis to halt eight rap-cel studies
2 min read
September 16, 2026
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
2 min read
September 16, 2026
As demand for GLP-1 medicines grows, injectable manufacturers must increase output without compromising quality or squeezing supply for other therapies
4 min read
September 15, 2026
Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control
2 min read
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
September 14, 2026
CD27-negative, CD39-negative CAR T cells were associated with treatment response when limited cell numbers were administered
3 min read
Receive the latest Medicine Maker news, personalities, education, and career development – weekly to your inbox.
False
